icer white paper affordable access to glp-1 obesity medications 2025 Big policy shift in medicine. Starting July 1, 2026, Medicare will launch a temporary “GLP-1 Bridge” program allowing eligible patients drugs like Zepbound and Wegovy for about $50/month. For ICER releases obesity medicines white

GHK-Cu, short for Glycyl-L-Histidyl-L-Lysine Copper, is a naturally occurring copper peptide that has garnered significant attention in the realm of health and wellness

If a GLP-1 medication is stopped, those conditions should be reassessed, since weight regain can increase medication requirements, he says

Compounded drugs can be important for overcoming shortages or meeting unique patient needsbut compounders should not try to compound drugs in a way that circumvents FDAs approval process. The FDA claims the companies are mass marketing their GLP-1s as similar alternatives to FDA-approved drugs

What is nutrient or infusion therapy